1. Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence 
Claudia Sommer, MD, Giorgio Cruccu, MD 
Journal of Pain and Symptom Management 
Volume 53, Issue 3, Pages (March 2017)
DOI: /j.jpainsymman
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1
Response rate after treatment with lidocaine 5% medicated plaster or pregabalin in patients with PHN and DPN (PPS).27CI = confidence interval; DPN = painful diabetic polyneuropathy; PHN = post-herpetic neuralgia; PPS = per protocol set. “*” Indicates below the predefined margin for noninferiority of −8 percentage points.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Treatment-emergent and drug-related adverse events with lidocaine 5% medicated plaster and pregabalin (SAS).27 AE = adverse event; SAS = safety analysis set.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Achievement of a ≥30% decrease in NPRS score from baseline to Week 8 (FAS) with capsaicin 8% patch vs. pregabalin.15 CI = confidence interval; FAS = full analysis set; NPRS = Numeric Pain Rating Scale.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 The Authors Terms and Conditions

5. Fig. 4
Treatment satisfaction scores for medication use at Week 8 with capsaicin 8% patch vs. pregabalin.15 CI = confidence interval; LS = least square; TSQM = Treatment Satisfaction Questionnaire for Medication.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 The Authors Terms and Conditions